- Home
- KALV vs TYG Comparison
KALV vs TYG Comparison
Compare KALV & TYG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- TYG
- Stock Information
- Founded
- KALV N/A
- TYG 2003
- Country
- KALV United States
- TYG United States
- Employees
- KALV N/A
- TYG N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- TYG Investment Managers
- Sector
- KALV Health Care
- TYG Finance
- Exchange
- KALV Nasdaq
- TYG Nasdaq
- Market Cap
- KALV 637.9M
- TYG 734.8M
- IPO Year
- KALV N/A
- TYG N/A
- Fundamental
- Price
- KALV $15.82
- TYG $42.64
- Analyst Decision
- KALV Strong Buy
- TYG
- Analyst Count
- KALV 9
- TYG 0
- Target Price
- KALV $26.29
- TYG N/A
- AVG Volume (30 Days)
- KALV 734.1K
- TYG 61.7K
- Earning Date
- KALV 09-09-2025
- TYG 01-01-0001
- Dividend Yield
- KALV N/A
- TYG 10.26%
- EPS Growth
- KALV N/A
- TYG N/A
- EPS
- KALV N/A
- TYG 5.19
- Revenue
- KALV N/A
- TYG $18,090,640.00
- Revenue This Year
- KALV N/A
- TYG N/A
- Revenue Next Year
- KALV $221.95
- TYG N/A
- P/E Ratio
- KALV N/A
- TYG $8.23
- Revenue Growth
- KALV N/A
- TYG 32.84
- 52 Week Low
- KALV $7.30
- TYG $33.73
- 52 Week High
- KALV $16.32
- TYG $48.76
- Technical
- Relative Strength Index (RSI)
- KALV 71.16
- TYG 44.61
- Support Level
- KALV $13.72
- TYG $42.00
- Resistance Level
- KALV $13.96
- TYG $43.40
- Average True Range (ATR)
- KALV 0.69
- TYG 0.46
- MACD
- KALV 0.31
- TYG -0.05
- Stochastic Oscillator
- KALV 99.15
- TYG 45.36
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About TYG Tortoise Energy Infrastructure Corporation
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.